Independent reporting on compounded semaglutide and tirzepatide, dosing protocols, clinical-trial evidence, FDA regulatory updates, and provider comparisons. Updated weekly by the GLP1OneRx editorial team.
Retatrutide Phase 3 results (May 2026 TRIUMPH-1): -28.3% weight loss at 80 weeks, full safety and dose data, what comes next.
Brand Wegovy $1,349/mo retail cash-pay vs compounded semaglutide $145/mo (NexLife 12-mo plan). The 85-90% gap explained.
Brand Zepbound via Lilly Direct $1,059/mo cash vs compounded tirzepatide $186/mo. OSA indication and how to choose.
5-step titration (0.25→2.4 mg), reconstitution math, missed-dose rules, side-effect management.
6-step titration (2.5→15 mg), 10 mg/mL vial math, dose-response curve from SURMOUNT-1.
Direct comparison: STEP-1 vs SURMOUNT-1, SURPASS-2 head-to-head, SELECT cardiovascular evidence, compounded pricing.
Manage nausea, GI symptoms, fatigue on GLP-1: protocols, timing, hold-dose criteria, red-flag symptoms.
FDA April 14, 2026 action: salt-form restrictions, DTC marketing crackdown, 503A vs 503B clarification.
Balanced NexLife review: 94/100 scorecard, strengths (flat-rate, six pharmacies, MD/DO, thousands served), trade-offs.
Preserve lean mass: 1.6-2.0 g/kg protein, 2-3x/wk resistance training, creatine, sarcopenia red flags.
8-point checklist: ingredient form, pharmacy disclosure, clinician credentials, pricing structure, red flags.
Foundayo (orforglipron) — first FDA-approved oral non-peptide GLP-1 (March 2026). vs compounded sema cost analysis.
GLP-1 stacking protocols 2026: CagriSema REDEFINE-1 -22.7%, BPC-157 for GI, GHK-Cu for skin. Evidence and what to skip.
Every Journal post is researched, written, and reviewed against our public editorial standards and medical review policy. We disclose every affiliate relationship — see our affiliate disclosure. Mistakes are documented in our public corrections log.